1227 related articles for article (PubMed ID: 29119217)
1. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
[TBL] [Abstract][Full Text] [Related]
2. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; Curran VH; Nutt DJ
Lancet Psychiatry; 2016 Jul; 3(7):619-27. PubMed ID: 27210031
[TBL] [Abstract][Full Text] [Related]
3. Trial of Psilocybin versus Escitalopram for Depression.
Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
[TBL] [Abstract][Full Text] [Related]
4. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
[TBL] [Abstract][Full Text] [Related]
5. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.
Stroud JB; Freeman TP; Leech R; Hindocha C; Lawn W; Nutt DJ; Curran HV; Carhart-Harris RL
Psychopharmacology (Berl); 2018 Feb; 235(2):459-466. PubMed ID: 29085980
[TBL] [Abstract][Full Text] [Related]
6. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.
Roseman L; Demetriou L; Wall MB; Nutt DJ; Carhart-Harris RL
Neuropharmacology; 2018 Nov; 142():263-269. PubMed ID: 29288686
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
[TBL] [Abstract][Full Text] [Related]
8. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Goodwin GM; Aaronson ST; Alvarez O; Arden PC; Baker A; Bennett JC; Bird C; Blom RE; Brennan C; Brusch D; Burke L; Campbell-Coker K; Carhart-Harris R; Cattell J; Daniel A; DeBattista C; Dunlop BW; Eisen K; Feifel D; Forbes M; Haumann HM; Hellerstein DJ; Hoppe AI; Husain MI; Jelen LA; Kamphuis J; Kawasaki J; Kelly JR; Key RE; Kishon R; Knatz Peck S; Knight G; Koolen MHB; Lean M; Licht RW; Maples-Keller JL; Mars J; Marwood L; McElhiney MC; Miller TL; Mirow A; Mistry S; Mletzko-Crowe T; Modlin LN; Nielsen RE; Nielson EM; Offerhaus SR; O'Keane V; Páleníček T; Printz D; Rademaker MC; van Reemst A; Reinholdt F; Repantis D; Rucker J; Rudow S; Ruffell S; Rush AJ; Schoevers RA; Seynaeve M; Shao S; Soares JC; Somers M; Stansfield SC; Sterling D; Strockis A; Tsai J; Visser L; Wahba M; Williams S; Young AH; Ywema P; Zisook S; Malievskaia E
N Engl J Med; 2022 Nov; 387(18):1637-1648. PubMed ID: 36322843
[TBL] [Abstract][Full Text] [Related]
9. Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.
Carrillo F; Sigman M; Fernández Slezak D; Ashton P; Fitzgerald L; Stroud J; Nutt DJ; Carhart-Harris RL
J Affect Disord; 2018 Apr; 230():84-86. PubMed ID: 29407543
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.
Agin-Liebes GI; Malone T; Yalch MM; Mennenga SE; Ponté KL; Guss J; Bossis AP; Grigsby J; Fischer S; Ross S
J Psychopharmacol; 2020 Feb; 34(2):155-166. PubMed ID: 31916890
[TBL] [Abstract][Full Text] [Related]
11. Effects of psilocybin therapy on personality structure.
Erritzoe D; Roseman L; Nour MM; MacLean K; Kaelen M; Nutt DJ; Carhart-Harris RL
Acta Psychiatr Scand; 2018 Nov; 138(5):368-378. PubMed ID: 29923178
[TBL] [Abstract][Full Text] [Related]
12. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.
Sloshower J; Skosnik PD; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
J Psychopharmacol; 2023 Jul; 37(7):698-706. PubMed ID: 36938991
[TBL] [Abstract][Full Text] [Related]
13. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.
Lyons T; Carhart-Harris RL
J Psychopharmacol; 2018 Jul; 32(7):811-819. PubMed ID: 29338538
[TBL] [Abstract][Full Text] [Related]
14. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
Haikazian S; Chen-Li DCJ; Johnson DE; Fancy F; Levinta A; Husain MI; Mansur RB; McIntyre RS; Rosenblat JD
Psychiatry Res; 2023 Nov; 329():115531. PubMed ID: 37844352
[TBL] [Abstract][Full Text] [Related]
15. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.
Palhano-Fontes F; Barreto D; Onias H; Andrade KC; Novaes MM; Pessoa JA; Mota-Rolim SA; Osório FL; Sanches R; Dos Santos RG; Tófoli LF; de Oliveira Silveira G; Yonamine M; Riba J; Santos FR; Silva-Junior AA; Alchieri JC; Galvão-Coelho NL; Lobão-Soares B; Hallak JEC; Arcoverde E; Maia-de-Oliveira JP; Araújo DB
Psychol Med; 2019 Mar; 49(4):655-663. PubMed ID: 29903051
[TBL] [Abstract][Full Text] [Related]
16. Next generation antidepressants with novel mechanisms for treatment resistant depression.
Chen MH; Tu PC; Su TP
Prog Brain Res; 2023; 278():149-168. PubMed ID: 37414491
[TBL] [Abstract][Full Text] [Related]
17. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
Moreno FA; Wiegand CB; Taitano EK; Delgado PL
J Clin Psychiatry; 2006 Nov; 67(11):1735-40. PubMed ID: 17196053
[TBL] [Abstract][Full Text] [Related]
19. [The use of psilocybin for treatment-resistant depression].
Johannesdottir A; Sigurdsson E
Laeknabladid; 2022 Sep; 108(9):403-410. PubMed ID: 36040772
[TBL] [Abstract][Full Text] [Related]
20. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
